Anaphylaxis Market Size, Epidemiological Facts, Key Players, Therapies and Market Report 2032

Anaphylaxis is an acute, life-threatening, generalized or systemic allergic reaction mediated by the degranulation of mast cells and basophils. The condition usually develops suddenly and gets worse very quickly.

by DelveInsight Anaphylaxis Market Market Insights, Epidemiology and Forecast-2032″ The report provides an in-depth understanding of anaphylaxis, historical and forecast epidemiology, and anaphylaxis market trends in the US, EU5 (Germany, Spain, Italy, France, and UK) and in Japan.

the Anaphylaxis Market The report provides an edge when developing business strategies, by understanding the trends shaping and driving the global Anaphylaxis market. A detailed review of the historical and forecast Anaphylaxis market is included in the report, covering drug awareness in the 7MM.

Some of the main highlights of the Anaphylaxis Market Report

  • A study titled “The Epidemiology of Anaphylaxis”, in which the lifetime prevalence of anaphylaxis was estimated at 0.05-2% in the United States and approximately 3% in Europe. The study also mentioned that in the UK, of patients presenting to paramedics and first responders, an estimated 0.2% have emergencies due to anaphylaxis.
  • Biphasic anaphylaxis is a recurrence of anaphylaxis after appropriate treatment. This occurs without further exposure to the allergen and strikes after the patient survives the initial attack.
  • Anaphylaxis develops rapidly, usually reaching peak severity within 5 to 30 minutes and may, rarely, last several days.
  • About 1 in 5 hospital admissions in England due to allergies was due to an anaphylactic reaction (4,070 in 20,318). This is an increase of 9.9% compared to the same period of the previous year. NICE guideline CG134 reported an estimate available in the UK that approximately 1 in 1,333 people in the English population had experienced anaphylaxis at some point in their life. However, a systematic review published in 2013 estimated that one in 300 people in Europe were affected by anaphylaxis at some point in their life.

Access a free copy of our latest sample report @

Overview of Anaphylaxis Epidemiology

The lifetime prevalence of anaphylaxis has been estimated to be between 1.6% and 5.1%. Medications and biting insects are the main triggers in adults, with food and biting insects being the most commonly implicated triggers in children and adolescents. Food allergies affect 8% to 11% of children and adults in the United States, while adverse drug reactions (ADRs) affect up to 10% of the population (and 20% of hospitalized patients), drug reactions hypersensitivity (HSR) accounting for 10%% of all adverse reactions.

Segmentation of Anaphylaxis Epidemiology in 7MM (2019-2032)

  • Anaphylaxis Prevalent Population
  • Diagnosed and treatable cases of anaphylaxis
  • Anaphylaxis Trigger-specific population

Overview of the Anaphylaxis Market

Anaphylaxis is variable and unpredictable. It can be benign and disappear spontaneously due to the endogenous production of compensatory mediators or it can be severe and progress in a few minutes to respiratory or cardiovascular damage and death. Treatment of anaphylaxis primarily involves the use of epinephrine to prevent possible progression to life-threatening manifestations. When the patient is admitted to the hospital, he can receive intravenous glucocorticoids and antihistamines. These medications help reduce inflammation in the airways, improving your ability to breathe. They may also be given beta-agonists such as albuterol to help with breathing, and may also be given supplemental oxygen to help the body get the oxygen it needs.

Symptoms of Anaphylaxis

Symptoms include dizziness or fainting, difficulty breathing such as rapid shallow breathing, wheezing, rapid heartbeat, clammy skin, confusion and anxiety, collapse or loss of consciousness . There may also be other allergy symptoms, including itching, rash (hives), nausea or vomiting, swelling (angioedema), or stomach pain.

Diagnosis of anaphylaxis

A blood test to measure the amount of a certain enzyme (tryptase) that can be elevated up to three hours after anaphylaxis is analyzed. Additionally, the patient is tested for allergies with skin tests or blood tests to help determine the trigger. The differential diagnosis of anaphylaxis includes breathing difficulties or circulatory collapse, including vasovagal reactions, globus hystericus, status asthmaticus, foreign body aspiration, pulmonary embolism, epiglottitis , myocardial infarction, carcinoid syndrome, hereditary angioedema, pheochromocytoma and others. Absent from vasovagal reactions are upper airway obstruction, bronchospasm, abdominal cramps, pruritus, urticaria, and angioedema. Pallor, syncope, diaphoresis, and nausea usually indicate a vasovagal reaction, but both can occur.

See Detailed Research Report Here @

Anaphylaxis Societies

  • Pfizer
  • Adamis Pharmaceuticals
  • Aqueous therapeutic
  • Wyss Institute and others

Anaphylaxis medications

  • Abbie Sense Technology
  • AQST-109
  • AQST-108
  • Symjepi
  • EpiPen and EpiPen Jr, and others

Evaluating Emerging Anaphylaxis Treatment

Anaphylaxis pipeline has potential key player, such as Aquestive Therapeutics, Wyss Institute and others. Anaphylaxis market dynamics are expected to change in the coming years due to improved research and development activities for the market to understand effective treatment options. The launch of emerging therapies is expected during the forecast period 2021-2030.


1. Key information

2. Executive Summary

3. Competitive intelligence analysis

4. Market overview at a glance

5. Background and overview of the disease

6. Patient journey

7. Epidemiology of Anaphylaxis and Patient Population

8. Treatment Algorithm, Current Treatment and Medical Practices

9. Unmet Needs

10. Key Parameters of Anaphylaxis Treatment

11. Marketed products

12. Emerging Therapies

13. Seven major market analyzes

14. Attribute analysis

15. 7MM: Market Outlook

16. Overview of Access and Reimbursement

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Abilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading business consultant and market research company focused exclusively on life sciences. It supports pharmaceutical companies by providing complete end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Ankit Nigam
E-mail: Send an email
Call: +19193216187
Address:304 S. Jones Boulevard #2432
City: Albany
State: New York
Country: United States